Year: 2025

GREENWICH, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQG) (NasdaqGS: OXSQH) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended September 30, 2025.On October 30, 2025, our Board of Directors declared the following distributions on our common stock:Month Ending Record Date Payment Date Amount Per ShareJanuary 31, 2026 January 16, 2026 January 30, 2026 $0.035February 28, 2026 February 13, 2026 February 27, 2026 $0.035March 31, 2026 March 17, 2026 March 31, 2026 $0.035 Net asset value (“NAV”) per share as of September 30, 2025 stood at $1.95, compared with a NAV per share on June 30, 2025 of $2.06.Net investment income (“NII”) was approximately $5.6 million, or $0.07 per share, for the...

Reiterates 2025 Outlook for Consolidated Revenue and Adjusted EBITDA Strengthened Balance Sheet and Extended Maturity Profile Through Recent FinancingsNet Income of $1.609 Billion for the Third Quarter Includes One-Time Gain Related to Merger with Windstream Consolidated Revenue and Adjusted EBITDA of $722.6 Million and $327.8 Million, Respectively, for the Third Quarter____________________________ LITTLE ROCK, Ark., Nov. 04, 2025 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the third quarter 2025. Key highlights during the quarter included:Consolidated Fiber Revenue Grew 13% Year-over-Year in the Third Quarter Kinetic Consumer Fiber Revenue Grew 26% Year-over-Year in the Third Quarter Kinetic Consumer Fiber Subscribers Grew 17% Year-over-Year in the Third Quarter Kinetic...

Business Wins and Strategic Initiatives Drove Revenue Growth While Demand Remained Stable  Higher Revenue Resulted in Gross Margin Improvement MARLBOROUGH, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2025.    Three Months Ended September 30,       Nine Months Ended September 30,      (In millions, except per share data and percentages)     2025       2024     Change     2025       2024     Change  Revenue   $ 250.8     $ 233.1     8 %   $ 729.3     $ 742.8     (2 )%Gross margin     39.5 %     23.2 %         38.7 %     33.4 %      Operating income (loss)   $ 7.9     $ (253.3 )   NM     $ 9.8     $ (222.2 )   NM  Operating margin     3.1 %   (108.7 )%         1.3 %     (29.9 )%      Net income (loss)   $ 7.5     $ (233.6 )   NM     $ 17.8     $ (189.3 )   NM  Earnings...

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million – $163 million and adjusted EBITDA of $9.0 – $13.0 million ZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributors APONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate...

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows:NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-end NXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosing NXP900 clinical drug-drug interaction study in healthy volunteers successfully completed supporting our strategy for combination therapy Poster...

Third quarter net income of $17.7 millionThird quarter Adjusted EBITDA of $39.3 millionDredging backlog of $934.5 million at September 30, 2025 HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 HighlightsRevenue was $195.2 million Total operating income was $28.1 million Net income was $17.7 million Adjusted EBITDA was $39.3 million Dredging backlog as of September 30, 2025 was $934.5 millionManagement Commentary Lasse Petterson, President and Chief Executive Officer, commented, “Great Lakes delivered another solid quarter, driven by strong project execution and high equipment utilization....

OTTAWA, Ontario, Nov. 04, 2025 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and nine-month periods ended September 30, 2025. All amounts are in Canadian dollars and reported under IFRS® Accounting Standards unless otherwise noted. “I am pleased with our performance thus far in 2025,” commented Dan Goldberg, Telesat’s President and CEO. “Our Telesat Lightspeed team continues to make good progress on both the engineering and commercial fronts, as we work toward an initial satellite launch late next year and toward further expanding our $1.1 billion Telesat Lightspeed backlog. On the GEO side of the business, the year has developed largely as we had expected, and we maintain our disciplined focus on maximizing...